AI Verdict
RNA has stronger fundamentals based on our AI analysis.
RNGE vs RNA Fundamental Comparison
| Metric | RNGE | RNA |
|---|---|---|
| Revenue | $3.7M | N/A |
| Net Income | $19.2M | N/A |
| Net Margin | 516.5% | N/A |
| ROE | 89.3% | N/A |
| ROA | 15.6% | N/A |
| Current Ratio | 0.74x | N/A |
| Debt/Equity | 0.08x | N/A |
| EPS | $0.18 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RNGE vs RNA: Frequently Asked Questions
Is RNGE or RNA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RNA has stronger fundamentals. RNGE is rated STRONG SELL (95% confidence) while RNA is rated SELL (20% confidence). This is not investment advice.
How does RNGE compare to RNA fundamentally?
RANGE IMPACT, INC. has ROE of 89.3% vs Atrium Therapeutics, Inc.'s N/A. Net margins are 516.5% vs N/A respectively.
Which stock pays higher dividends, RNGE or RNA?
RNGE has a dividend yield of N/A or no dividend while RNA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RNGE or RNA for long term?
For long-term investing, consider that RNGE has STRONG SELL rating with 95% confidence, while RNA has SELL rating with 20% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RNGE vs RNA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RNGE vs RNA, the AI consensus favors RNA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.